HOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS
5PSQ-077
BEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY
5PSQ-074
COVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE
5PSQ-059
CHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL
5PSQ-057
ACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING
5PSQ-041
SAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW
5PSQ-038
DEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE
5PSQ-035
INTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD”
5PSQ-033
Positive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany
5PSQ-032
COMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING
5PSQ-030
USE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS
5PSQ-028
ASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT
5PSQ-027
Misuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units
5PSQ-017
MAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY
5PSQ-016
ACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE?
